Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)

NCT ID: NCT00221962

Last Updated: 2014-12-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-04-30
• Study Completion Date: 2007-04-30

Brief Summary

To look at the cognitive effects of abilify in children with a primary diagnosis of Attention Deficit Hyperactivity Disorder. To examine the safety, effectiveness and tolerability of abilify in children with a primary diagnosis of Attention Deficit Hyperactivity Disorder.

Detailed Description

This will be a prospective, open-label, 6-week trial of APZ in outpatient children 8-12 years of age with a primary diagnosis of ADHD free of other major psychopathology. The six-week treatment phase will be proceeded by a 1-3 week screening phase.

The study cohort will consist of 10 children with ADHD combined type and 10 children with ADHD predominantly inattentive type who complete the study.

Cognitive measures will be assessed prior to APZ therapy and after 6 weeks of APZ treatment.

Safety assessments and measures of ADHD symptomatology will be collected prior to and during APZ therapy.

While receiving APZ treatment, patients will be seen at baseline, Week 1,2,3,4, and 6.

Conditions

Attention Deficit Hyperactivity Disorder

Keywords

ADHD

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Open label treatment with aripiprazole

After 1-3 week screening phase, entered six week open trial of aripiprazole initiated at 2.5mg/day. DOsing was increased weekly in 2.5mg increments in order to reach maximum dose of 10mg/d.

Group Type: OTHER

Aripiprazole

Intervention Type: DRUG

Open label

Interventions

Aripiprazole

Open label

Intervention Type: DRUG

Other Intervention Names

As previously described.

Eligibility Criteria

Inclusion Criteria

1. Outpatients ages 8-12 years (inclusive)

2. Currently meets DSM-IV (American Psychiatric Association, 1994) criteria for a primary diagnosis of ADHD (either predominantly inattentive type or combined type) based on the results of semi-structured diagnostic assessment (K-SADS-PL)(Kaufman et al., 1997) and based on the results of a clinical interview with a child and adolescent psychiatrist

3. Patients, who in the investigator's opinion, have substantial symptoms of ADHD for which pharmacotherapy is indicated

4. Has a guardian who has provided written informed consent to participate in this trial

5. Has provided written informed assent to participate in this study

Exclusion Criteria

1. Patients who have a history of intolerance to APZ at a dose of 5 mg/day

2. Patients with a history of APZ allergy or hypersensitivity to APZ

3. Patients with an active or prior neurological/medical disorder for which treatment with APZ would be contraindicated (such as tardive dyskinesia or neuroleptic malignant syndrome)

4. Patients with clinical evidence of autistic disorder, Rett's syndrome or Asperger's syndrome

5. Patients with any bipolar spectrum disorder

6. Patients with any schizophrenia spectrum disorder

7. Patients with conduct disorder

8. Patients with post-traumatic stress disorder or generalized anxiety disorder

9. Patients with a substance abuse disorder

10. Females who are sexually active, pregnant or lactating

11. Patients with a suicide attempt requiring medical/psychiatric care within the past 6 months

12. Patient taking psychotropic agents within one week of baseline (3 days for psychostimulants, 2 weeks for fluoxetine)

13. Patients with evidence of mental retardation (I.Q. < 70) based on the results of the Peabody Picture Vocabulary Test- III (PPVT-III)(Dunn and Dunn, 1981)

14. Patients who have a general medical or neurological condition that could interfere with the interpretation of the clinical response to APZ treatment

15. Patients who are unable to swallow pills or capsules

16. Patients for whom the need for hospitalization during the course of the study appears likely

• Minimum Eligible Age: 8 Years
• Maximum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

University Hospitals Cleveland Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Robert L Findling, MD

Director, Child and Adolescent Psychiatry

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Robert L Findling, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospitals Cleveland Medical Center

Locations

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Countries

United States

References

Findling RL, Short EJ, Leskovec T, Townsend LD, Demeter CA, McNamara NK, Stansbrey RJ. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008 Aug;18(4):347-54. doi: 10.1089/cap.2007.0124.

Reference Type: DERIVED

PMID: 18759644 (View on PubMed)

Other Identifiers

cognition

Identifier Type: -

Identifier Source: org_study_id